Inhibitor Therapeutics (INTI) Ownership - Who Owns Inhibitor Therapeutics?
Inhibitor Therapeutics (INTI) Ownership Overview
- 26.75% Insiders
- 73.25% Public Companies and Individual Investors
The ownership structure of Inhibitor Therapeutics (INTI) stock is a mix of institutional, retail, and individual investors. , 26.75% is owned by Insiders, and 73.25% is owned by Public Companies and Individual Investors.
The ownership structure of Inhibitor Therapeutics (INTI) stock is a mix of institutional, retail, and individual investors. Approximately 73.25% of the company’s stock is owned by Institutional Investors, 26.75% is owned by Insiders
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Ronald E Osman | 23,614,985 | Insider | 13.59% | 2,267,039 |
| Black Robe Capital Llc | 19,901,057 | Insider | 11.45% | 1,910,501 |
| Samuel Sears | 1,229,543 | Insider | 0.71% | 118,036 |
| Michelle Yanez | 1,221,271 | Insider | 0.70% | 117,242 |
| Niraj Vasisht | 200,000 | Insider | 0.12% | 19,200 |
| Michael Allen Jerman | 180,411 | Insider | 0.10% | 17,319 |
| Francis Odonnell | 150,000 | Insider | 0.09% | 14,400 |
FAQ
What percentage of Inhibitor Therapeutics (INTI) stock is held by retail investors?
According to the latest TipRanks data, approximately 73.25% of Inhibitor Therapeutics (INTI) stock is held by retail investors.
Who owns the most shares of Inhibitor Therapeutics (INTI)?
Ronald E Osman owns the most shares of Inhibitor Therapeutics (INTI).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.